<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228357</url>
  </required_header>
  <id_info>
    <org_study_id>2003-08-07</org_study_id>
    <nct_id>NCT01228357</nct_id>
  </id_info>
  <brief_title>Predict Antidepressant Responsiveness Using Pharmacogenomics</brief_title>
  <official_title>Predict Antidepressant Responsiveness Using Pharmacogenomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether genetic information associated with
      individual depressive symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is that the variations of the candidate genes are associated with
      individual symptoms in patients with depression.

      The Second hypothesis is that patients with the associated genetic variation suffer longer
      from the associated symptom than the patients without the associated genetic variation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presences of each individual symptom of depression at 1,2,4,6,12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>17-items HAM-D scale was employed to measure depressive symptoms</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>SSRI treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-SSRI treated group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SSRI treated group</intervention_name>
    <description>Antidepressant administration of SSRI class for 12 weeks under therapeutic dose</description>
    <arm_group_label>SSRI treated group</arm_group_label>
    <other_name>fluoxetine_Prozac</other_name>
    <other_name>paroxetine_Paxil, Seroxat</other_name>
    <other_name>sertraline_Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-SSRI treated group</intervention_name>
    <description>Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose</description>
    <arm_group_label>non-SSRI treated group</arm_group_label>
    <other_name>milnacipran</other_name>
    <other_name>venlafaxine_Effexor</other_name>
    <other_name>nortriptyline_Aventyl, Pamelor, Noritren</other_name>
    <other_name>mirtazapine_Avanza, Zispin, Remeron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients were enrolled in the clinical trials program of hte Samsung Medical
             Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a
             semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The
             affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the
             Korean version of the structured clinical interview for the diagnostic and statistical
             manual of mental disorders, Fourth edition.

          -  interview with one more patient's family member for objective diagnosis and final
             diagnosis decision by agreements of two more psychiatric physicians

        Exclusion Criteria:

          -  received psychotropic medication within 2 weeks of the study or fluoxetine within 4
             weeks

          -  potential study participants for pregnancy, significant medical conditions, abnormal
             laboratory baseline values, unstable psychiatric features(eg.suicidal), history of
             alcohol of drug dependence, seizures, head trauma with loss of consciousness,
             neurological illness, or concomitant Axis I psychiatric disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JungShil Back, B/Sc.</last_name>
    <phone>82-2-3410-0946</phone>
    <email>jungshil.back@sbri.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shinn-Won Lim, phD</last_name>
    <phone>82-2-3410-3759</phone>
    <email>shinwon.lim@sbri.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doh Kwan Kim, MD.PhD</last_name>
      <phone>82-2-3410-3582</phone>
      <email>dohkwan.kim@samsung.com</email>
    </contact>
    <contact_backup>
      <last_name>Woojae Myung, MD.</last_name>
      <phone>82-2-3410-6562</phone>
      <email>smbhealer@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2010</study_first_submitted>
  <study_first_submitted_qc>October 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Depressed Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

